BTK Inhibitors as Sensitizing Agents in Solid Tumors

BTK Inhibitors as Sensitizing Agents in Solid Tumors provides a thorough review of mechanisms of multi-drug resistance in cancers, and describes in detail the mechanisms, current studies, and future directions of the role of BTK inhibitors in overcoming therapy resistance in cancer, including resistance to chemotherapy, targeted therapies, and immunotherapy. The book discusses topics such as mechanisms of therapy resistance in cancer cells; BTK inhibitors in paclitaxel, docetaxel, platinum, BRAF, and radio resistance. In addition, it discusses ibrutinib and its role in immunotherapy resistance, novel BTK inhibitors and future perspectives. It is a valuable resource for cancer researchers, oncologists, graduate students, and members of biomedical field who are interested in the potential of BTK inhibitors as sensitizing agent to resistant cancers. Provides a unique compilation of cutting-edge research on the emerging role of BTK inhibitors as chemosensitizers Focuses on pre-clinical and clinical studies addressing efficacy of BTK inhibitors in treatment of multi-drug resistant cancers Presents data, perspectives and thoughts from leading researchers who compile their knowledge on the topic based on their research work and clinical expertise INDICE: 1. Overview of BTK pathway2. Overview of BTK inhibitors and their clinical utility [1st gen, 2nd gen]3. Mechanisms of therapy resistance in cancer cells4. BTK inhibitors in paclitaxel and docetaxel resistance5. BTK inhibitors in Platinum resistance6. BTK inhibitors in BRAF resistance7. BTK inhibitors in radio-resistance8. Ibrutinib beyond BTK inhibition and role in immunotherapy resistance9. Novel BTK inhibitors and future perspectives

• ISBN: 978-0-323-95239-2
• Editorial: Academic Press
• Encuadernacion: Cartoné
• Fecha Publicación: 01/11/2022
• Nº Volúmenes: 1
• Idioma: Inglés